secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-08-12T20:10:19+00:00
Accession:  0001193125-26-346856
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Q2: KOMZIFTI revenue $9.1M, majority share in NPM1-m AML menin class
-------------------------------------------------------------------------

- KOMZIFTI net product revenue $9.1M, up 57% QoQ; ~115 new patient starts, up 35% QoQ.
- Achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class.
- EHA 2026 KOMET-007: CRc 96% (NPM1-m) and 90% (KMT2A-r) with 600mg ziftomenib+7+3; 12-mo OS 94%/71%.
- Net loss $68.3M; cash $519.0M plus $180M anticipated Kyowa Kirin payments fund through 2028 pivotal readout.
- Darlifarnib combo data: 67% ORR pancreatic, 50% NSCLC in KRAS G12C; ccRCC ORR up to 50%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/0001193125-26-346856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer